Form 4: TScan Therapeutics Director Receives Stock Option Grant

Director Katina Dorton was granted 67,000 stock options in TScan Therapeutics, Inc. as part of a standard equity compensation arrangement.

Summary

• Director Katina Dorton acquired 67,000 stock options in TScan Therapeutics, Inc. (TCRX).
• The options have an exercise price of $0.9946 per share.
• The grant date for these options is May 20, 2026.
• The options are set to expire on May 20, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock relative to the exercise price.

Future Outlook

The options vest in full on the earlier of May 20, 2027, or the date of the next annual meeting of stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise while aligning incentives with corporate performance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for small-cap biotechnology firms.
• The use of stock options as a primary equity vehicle is standard for companies in the clinical development stage.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on May 20, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

TScan Therapeutics, TCRX, Form 4, Insider Trading, Stock Options, Director Compensation